JK07: Selective ErbB4 Agonist & Potential First Disease-Modifying Biologic for Heart Failure Across the Ejection Fraction Spectrum
Time: 9:10 am
day: Summit Day 2
Details:
- Discussing JK07, an NRG1/ErbB3 antibody fusion, and the first selective ErbB4 agonist in clinical development for heart failure, with unique potential to increase contractility and reduce fibrosis in the myocardium
- Evaluating phase 1b data in heart failure with reduced ejection fraction (HFrEF) subjects where the potential to increase LVEF durably with a single, well-tolerated dose was demonstrated
- Updating on ongoing 282-subject Phase 2 study in HFrEF and heart failure with preserved ejection fraction (HFpEF), to assess repeat dosing of two dose levels and three dose regimens on myocardial function, quality of life, functional capacity, and cardiovascular outcomes
